GLUE Stock Overview
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins.
Monte Rosa Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.19|
|52 Week High||US$45.56|
|52 Week Low||US$7.22|
|1 Month Change||-40.09%|
|3 Month Change||-36.56%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-61.33%|
Recent News & Updates
We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|GLUE||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how GLUE performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GLUE performed against the US Market.
|GLUE Average Weekly Movement||12.8%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: GLUE is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: GLUE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn’s disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies.
Monte Rosa Therapeutics Fundamentals Summary
|GLUE fundamental statistics|
Is GLUE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|GLUE income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.84|
|Net Profit Margin||0.00%|
How did GLUE perform over the long term?See historical performance and comparison
Is Monte Rosa Therapeutics undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GLUE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GLUE's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: GLUE is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: GLUE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GLUE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GLUE is good value based on its PB Ratio (1.2x) compared to the US Biotechs industry average (1.4x).
How is Monte Rosa Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GLUE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GLUE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GLUE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GLUE is forecast to have no revenue next year.
High Growth Revenue: GLUE is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GLUE is forecast to be unprofitable in 3 years.
How has Monte Rosa Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: GLUE is currently unprofitable.
Growing Profit Margin: GLUE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GLUE's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GLUE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: GLUE has a negative Return on Equity (-26.27%), as it is currently unprofitable.
How is Monte Rosa Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: GLUE's short term assets ($320.4M) exceed its short term liabilities ($12.5M).
Long Term Liabilities: GLUE's short term assets ($320.4M) exceed its long term liabilities ($7.6M).
Debt to Equity History and Analysis
Debt Level: GLUE is debt free.
Reducing Debt: GLUE had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GLUE has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: GLUE has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 1.3% each year.
What is Monte Rosa Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GLUE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GLUE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GLUE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GLUE's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GLUE has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Markus Warmuth (50 yo)
Dr. Markus Warmuth, M.D., serves on Board of Directors of Ventus Therapeutics U.S., Inc. since December 7, 2021. He serves as President, Chief Executive Officer and Director at Monte Rosa Therapeutics, Inc...
CEO Compensation Analysis
Compensation vs Market: Markus's total compensation ($USD4.95M) is above average for companies of similar size in the US market ($USD2.65M).
Compensation vs Earnings: Markus's compensation has increased whilst the company is unprofitable.
Experienced Management: GLUE's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: GLUE's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: GLUE only recently listed within the past 12 months.
Monte Rosa Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Monte Rosa Therapeutics, Inc.
- Ticker: GLUE
- Exchange: NasdaqGS
- Founded: 2019
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$380.381m
- Shares outstanding: 46.44m
- Website: https://www.monterosatx.com
Number of Employees
- Monte Rosa Therapeutics, Inc.
- 645 Summer Street
- Suite 102
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.